丙丁酚治疗非增殖性糖尿病视网膜病变的临床观察

Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy

摘要: 目的：观察丙丁酚治疗非增殖性糖尿病视网膜病变(NPDR)的临床疗效。方法：于2012年1月至2013年8月选取非增殖性糖尿病视网膜病变患者68例作为研究对象，再将非增殖性糖尿病视网膜病变(NPDR)患者分为四组：即：A组、强化治疗+丙丁酚组，共17例；B组、强化治疗组，共17例；C组、常规治疗 + 丙丁酚组，共17例；D组、常规治疗组，共17例，避免服用其它抗氧化剂。A、C组DR患者予丙丁酚0.375 g，每日2次。平均随访11.58 ± 0.17个月。并比较观察4组干预前、1年后的视力、眼底及血脂(TC、LDLC)变化。结果：最终随访发现：1、A、C组NPDR患者的眼底情况较干预前显著改善(P < 0.05)，A、C组间干预后眼底情况无显著性差异(P > 0.05)；B、D组患者的眼底情况均无显著改善(P > 0.05)。2、A、C组患者最佳矫正视力均较干预前显著提高(P < 0.05)，A、C组间干预后最佳矫正视力无显著性差异(P > 0.05)；B、D组患者最佳矫正视力均无显著提高(P > 0.05)。3、A、C组患者TC、LDLC水平均显著低于干预前(P < 0.05)；B、D组干预前后血脂水平无显著性差异(P > 0.05)；且干预后A、C组间TC、LDLC水平无显著性差异(P > 0.05)。结论 丙丁酚治疗非增殖性糖尿病视网膜病变疗效显著，且并发症较少。

Abstract: Objective: To observe the clinical efficacy of probucol for nonproliferative diabetic retinopathy (NPDR). Methods: 68 patients with nonproliferative diabetic retinopathy (NPDR) were studied from Jan. 2012 to Aug. 2013. These patients were divided into four groups. Group A consisted of 17 patients receiving enhanced therapy and probucol; Group B consisted of 17 patients receiving enhanced therapy; Group C consisted of 17 patients receiving regular therapy and probucol; Group D consisted of 17 patients receiving regular therapy. Group A and Group C were given probucol of 0.375 g twice per day. All patients were followed up for average 11.58 ± 0.17 months. The changes of best corrected visual acuity, fundus, total cholesterol (TC), low density lipoprotein- cholesterol (LDL-C) before therapy and one year after therapy were observed. Results: 1) The fundi of Group A and Group C were significantly improved (P < 0.05), and there was no significant difference between the fundi of Group A and of Group C after therapy (P > 0.05); but the difference between the fundi of Group B and of Group D was not statistically significant (P > 0.05). 2) The best corrected visual acuity of Group A and Group C was improved significantly (P < 0.05), and there was no significant difference between the best corrected visual acuity of Group A and of Group C (P > 0.05); but the best corrected visual acuity of Group B and Group D did not change significantly (P > 0.05). 3) The TC and LDLC level of Group A and Group C decreased significantly (P < 0.05); The TC and LDLC level of Group B and Group D did not change significantly (P > 0.05); There was no significant difference between the TC and LDLC level of Group A and of Group C (P > 0.05). Conclusion: The efficacy of probucol for nonproliferative diabetic retinopathy is significant with less complications.